Tasly Pharmaceutical Group Co., Ltd. announced earnings results for the first quarter of 2017. For the period, the company’s operates revenue climbing 6.45% from a year earlier to CNY 3.35 billion. Net profit deducting non-recurring profit and loss leaped 15.19% to CNY 311 million, representing CNY 0.2945 per share. Weighted average return on net assets was 3.92%.